Evolución en el diagnóstico y manejo del esófago de Barrett: 2004-2014

  • Rodrigo Castaño Instituto de Cancerología de la Clínica las Américas
Palabras clave: Esófago de Barrett, diagnóstico, tratamiento

Descargas

La descarga de datos todavía no está disponible.

Biografía del autor/a

Rodrigo Castaño, Instituto de Cancerología de la Clínica las Américas

Médico Cirujano Gastrointestinal. Jefe de Postgrado de Cirugía General Universidad Pontificia Bolivariana, Grupo de Gastrohepatología de la Universidad de Antioquia, Instituto de Cancerología de la Clínica las Américas. Medellín, Colombia. Correo electrónico: rcastanoll@hotmail.com

Referencias bibliográficas

Clemons NJ, Koh SY, Phillips WA. Advances in understanding the pathogenesis of Barrett’s esophagus. Discovery medicine 2014; 17: 7-14.

Spechler SJ. Barrett’s esophagus: is the goblet half empty? Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 2012; 10: 1237-8.

Westerhoff M, Hovan L, Lee C, Hart J. Effects of dropping the requirement for goblet cells from the diagnosis of Barrett’s esophagus. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 2012; 10: 1232-6.

Hvid-Jensen F, Pedersen L, Drewes AM, Sorensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett’s esophagus. The New England journal of medicine 2011; 365: 1375-83.

Kastelein F, Spaander MC, Steyerberg EW, et al. Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett’s esophagus. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 2013; 11: 382-8.

Boerwinkel DF, Swager AF, Curvers WL, Bergman JJ. The Clinical Consequences of Advanced Imaging Techniques in Barrett’s Esophagus. Gastroenterology 2014.

Kariyawasam VC, Bourke MJ, Hourigan LF, et al. Circumferential location predicts the risk of high-grade dysplasia and early adenocarcinoma in short-segment Barrett’s esophagus. Gastrointestinal endoscopy 2012; 75: 938-44.

Bergeron EJ, Lin J, Chang AC, Orringer MB, Reddy RM. Endoscopic ultrasound is inadequate to determine which T1/T2 esophageal tumors are candidates for endoluminal therapies. The Journal of thoracic and cardiovascular surgery 2014; 147: 765-71: Discussion 71-3.

Orman ES, Li N, Shaheen NJ. Efficacy and durability of radiofrequency ablation for Barrett’s Esophagus: systematic review and meta-analysis. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 2013; 11: 1245-55.

Orman ES, Kim HP, Bulsiewicz WJ, et al. Intestinal metaplasia recurs infrequently in patients successfully treated for Barrett’s esophagus with radiofrequency ablation. The American journal of gastroenterology 2013; 108: 187-95; quiz 96.

Downs-Kelly E, Mendelin JE, Bennett AE, et al. Poor interobserver agreement in the distinction of high-grade dysplasia and adenocarcinoma in pretreatment Barrett’s esophagus biopsies. The American journal of gastroenterology 2008; 103: 2333-40; quiz 41.

Sikkema M, Looman CW, Steyerberg EW, et al. Predictors for neoplastic progression in patients with Barrett’s Esophagus: a prospective cohort study. The American journal of gastroenterology 2011; 106: 1231-8.

Curvers WL, ten Kate FJ, Krishnadath KK, et al. Low-grade dysplasia in Barrett’s esophagus: overdiagnosed and underestimated. The American journal of gastroenterology 2010; 105: 1523-30.

Phoa KN, Pouw RE, van Vilsteren FG, et al. Remission of Barrett’s esophagus with early neoplasia 5 years after radiofrequency ablation with endoscopic resection: a Netherlands cohort study. Gastroenterology 2013; 145: 96-104.

Phoa KN, van Vilsteren FG, Weusten BL, et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA: the journal of the American Medical Association 2014; 311: 1209-17.

Mokrowiecka A, Wierzchniewska-Lawska A, Smolarz B, et al. Amplification of Her-2/neu oncogene in GERD - Barrett’s metaplasia - dysplasia - adenocarcinoma sequence. Hepato-gastroenterology 2013; 60: 1063-6.

Bird-Lieberman EL, Dunn JM, Coleman HG, et al. Population-based study reveals new risk-stratification biomarker panel for Barrett’s esophagus. Gastroenterology 2012; 143: 927-35 e3.

Prasad GA, Wang KK, Halling KC, et al. Utility of biomarkers in prediction of response to ablative therapy in Barrett’s esophagus. Gastroenterology 2008; 135: 370-9.

Lee JK, Cameron RG, Binmoeller KF, et al. Recurrence of subsquamous dysplasia and carcinoma after successful endoscopic and radiofrequency ablation therapy for dysplastic Barrett’s esophagus. Endoscopy 2013; 45: 571-4.

Álvarez Herrero L, Curvers WL, Bisschops R, et al. Narrow band imaging does not reliably predict residual intestinal metaplasia after radiofrequency ablation at the neo-squamo columnar junction. Endoscopy 2014; 46: 98-104.

Publicado
2014-12-30
Cómo citar
Castaño Llano, R. (2014). Evolución en el diagnóstico y manejo del esófago de Barrett: 2004-2014. Revista Colombiana De Gastroenterología, 29(4), 337-340. https://doi.org/10.22516/25007440.420